This website is for UK and Ireland Healthcare professionals only.

If you are not a healthcare professional in the UK, please click here.

If you are not a healthcare professional in Ireland, please click here.

Eliquis® (apixaban)

Risk Minimisation Information for Healthcare Professionals

Knowledge test: risk minimisation and bleeding management

Check your understanding of the important content of this website by answering the following questions.

There are six questions. Please answer as many as you can, and preferably all six questions.

Thank you for answering the questions.

1. While a patient is being treated with apixaban, it is important that early recognition and immediate contact with a healthcare professional is made for signs and/or symptoms of which associated risk?

  • Increased blood pressure
  • Bleeding that doesn’t stop on its own
  • Suppressed immunity over an extended period
  • Neutropenia
  • I don’t know/I’m not sure

2. In which one of the following patient groups is the prescribing of apixaban NOT contraindicated?

  • First-degree relative family history of haemorrhagic stroke
  • Current or recent gastrointestinal ulceration
  • Patients with cancers at high risk of bleeding
  • Recent brain or spinal injury
  • I don’t know/I’m not sure

3. Which one of the following should a prescriber NOT tell patients?

  • To carry the Patient Alert Card with them at all times
  • When to seek attention from a healthcare professional
  • To show the Patient Alert Card only to other specialists
  • To inform healthcare professionals that they are taking apixaban if they require surgery or invasive procedures
  • I don’t know/I’m not sure

4. Which of these patient subpopulations would be at increased risk of bleeding if treated with apixaban? (Select all that apply)

  • Patients with severe renal impairment (CrCl 15-29 ml/min)
  • Patients taking strong inhibitors of both CYP3A4 and P-gp
  • Patients taking oral contraceptives
  • Patients who have recently undergone brain, ophthalmic or spinal surgery
  • Patients taking Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Patients with significant dyspepsia, GORD, or other upper GI disorders

5. If a patient treated with apixaban requires surgery associated with a moderate risk of bleeding, what course of action should be taken?

  • Stop apixaban at least 2 weeks before the surgery
  • Stop apixaban at least 48 hours before the surgery
  • Stop apixaban at least 24 hours before the surgery
  • Continue apixaban at the currently prescribed dose
  • I don’t know/I’m not sure

6. Is routine coagulation monitoring required in patients taking apixaban?

  • Yes, for all patients
  • Yes, for high-risk patients only
  • No
  • I don’t know/I’m not sure